[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100589250":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":26,"centralContacts":30,"locations":36,"responsibleParty":51,"collaborators":21,"id":53,"slug":21,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":21,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":21,"studyType":65,"phases":66,"briefSummary":69,"conditions":70,"keywords":21,"overallStatus":72,"whyStopped":21,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"The First Affiliated Hospital of Soochow University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"E-Ru for HLH","EXPERIMENTAL","dose-modified Emapalumab+Ruxolitinib for the treatment of HLH patients.",[13,14],"Drug: dose-modified E-Ru","Other: Salvage treatment and follow-up",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","dose-modified E-Ru","Emapalumab (1-2 mg\u002Fkg intravenously once weekly for 8 weeks) + Ruxolitinib (15-30 mg orally twice daily for 8 weeks)",[9],null,{"type":6,"name":23,"description":24,"armGroupLabels":25,"otherNames":21},"Salvage treatment and follow-up","1\\) for patients who did not respond to the E-Ru regimen after 7 days or who relapsed at any point during treatment, a rescue regimen such as HLH-94 or doxorubicin-etoposide-methylprednisolone (DEP) was administered; 2) for patients diagnosed with lymphoma after enrollment, chemotherapy was initiated; 3) for patients who completed 8 weeks of treatment without recurrence and had no detected HLH-related gene mutations, follow-up was initiated; and 4) for patients who met the criteria for allo-HSCT, allo-HSCT was performed.",[9],[27],{"name":28,"affiliation":5,"role":29},"Xuefeng He, Dr.","PRINCIPAL_INVESTIGATOR",[31],{"name":32,"role":33,"phone":34,"phoneExt":21,"email":35},"Yue Song, Dr","CONTACT","+86 18810253070","xueqifeng1992@163.com",[37],{"facility":5,"status":21,"city":38,"state":39,"zip":40,"country":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Suzhou","Jiangsu","215006","China",{"type":43,"coordinates":44},"Point",[45,46],120.59538,31.30408,{"lat":46,"lon":45},[49],{"name":50,"role":33,"phone":34,"phoneExt":21,"email":35},"Yue Song, Dr.",{"type":29,"investigatorFullName":52,"investigatorTitle":5,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"Xuefeng He","100589250",false,"NCT06951971","Dose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic Lymphohistiocytosis","A Multiple Center, Prospective, Single Arm, Phase III Clinical Study to Evaluate the Efficacy and Safety of Dose-modified Emapalumab and Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis","Inclusion Criteria:\n\n1. Fulfillment of at least five of the eight HLH-2004 criteria for HLH;\n2. Age 1-70 years old;\n3. No prior chemotherapy for HLH;\n4. Confirmed not pregnant and willing to use effective contraceptive measures during the study period, with the last dose of medication administered at least 12 months prior;\n5. Signed informed consent prior to study participation.\n\nExclusion Criteria:\n\n1. According to the New York Heart Association (NYHA) score, patients with heart disease of grade II or above (including grade II);\n2. HIV-infected patients;\n3. Patients with severe renal dysfunction (glomerular filtration rate \\\u003C15 mL\u002Fmin);\n4. Patients with severe liver cirrhosis (MELD score\\>20);\n5. Uncontrollable infections (including lung infections, intestinal infections, etc.);\n6. Have serious mental illness;\n7. Have a history of active tumor;\n8. Participate in other clinical investigators at the same time;\n9. People with central nervous system involvement;\n10. Exclusion criteria related to concomitant medication.","ALL","1 Year","70 Years",{"count":63,"type":64},30,"ESTIMATED","INTERVENTIONAL",[67,68],"PHASE2","PHASE3","This study is trying to evaluate the efficacy and safety of dose-modified Emapalumab and Ruxolitinib (E-Ru) regimens for the treatment of active hemophagocytic lymphohistiocytosis.",[71],"Hemophagocytic Lymphohistiocytosis (HLH)","NOT_YET_RECRUITING","2025-04-23",{"date":75,"type":76},"2025-04-30","ACTUAL",{"date":78,"type":64},"2025-06-01",{"date":80,"type":64},"2028-06-01",{"name":5,"class":6},1]